Spots Global Cancer Trial Database for Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
Official Title: A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
Study ID: NCT04308395
Conditions
Interventions
Study Description
Brief Summary: This is a multicenter, open label extension study evaluating the safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult subjects with Gorlin syndrome.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
PellePharm Investigative Site, Fremont, California, United States
PellePharm Investigative Site, Newport Beach, California, United States
Yale University, New Haven, Connecticut, United States
Pellepharm Investigative Site, Miami, Florida, United States
PellePharm Investigative Site, Ormond Beach, Florida, United States
PellePharm Investigative Site, Chicago, Illinois, United States
Laser & Skin Surgery Center of Indiana, Indianapolis, Indiana, United States
Pellepharm Investigative Site, Ann Arbor, Michigan, United States
University of Minnesota, Minneapolis, Minnesota, United States
Saint Louis University, Saint Louis, Missouri, United States
Columbia University Irving Medical Center, New York, New York, United States
Duke University Medical Center, Durham, North Carolina, United States
Cleveland Clinic, Cleveland, Ohio, United States
Oregon Health and Science University, Portland, Oregon, United States
Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
MD Anderson Cancer Center, Houston, Texas, United States
University of Utah, Midvalley Dermatology, Murray, Utah, United States
PellePhram Investigative Site, Leuven, , Belgium
PellePharm Investigative Site, Copenhagen, , Denmark
PellePharm Investigative Site, Lille, , France
PellePharm Investigative Site, Nantes, , France
Hopital Saint Louis, Paris, , France
PellePharm Investigative Site, Berlin, , Germany
PellePharm Investigative Site, Munich, , Germany
PellePharm Investigative Site, Münster, , Germany
AOU Luigi Vanvitelli, Napoli, , Italy
PellePharm Investigative Site, Rozzano, , Italy
PellePharm Investigative Site, Vicenza, , Italy
PellePharm Investigative Site, Maastricht, , Netherlands
PellePharm Investigative Site, Barcelona, , Spain
PellePharm Investigative Site, Madrid, , Spain
PellePharm Investigative Site, Madrid, , Spain
PellePharm Investigative Site, Sevilla, , Spain
PellePharm Investigative Site, Glasgow, , United Kingdom
PellePharm Investigative Site, London, , United Kingdom
PellePharm Investigative Site, Manchester, , United Kingdom
PellePharm Investigative Site, Oxford, , United Kingdom
Contact Details
Name: Study Director VP, Clinical Operations
Affiliation: PellePharm, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
